N-Azacytidine Inhibits Myeloma Cell Growth While Preserving Multiple Myeloma Patient Derived-Bone Marrow Mesenchymal Stromal Cells Differentiation
Metabolites · 31.07.2026 · 16 (8) · 540
DOI: 10.3390/metabo16080540 ↗Kurz gefasst
Fachartikel in der Zeitschrift Metabolites, online erschienen am 31.07.2026. Verfasst von Tamara Kukolj und 7 weiteren Autor:innen. Beteiligte Einrichtung: Group for Hematology and Stem Cells, Institute for Medical Research, National Institute of the Republic of Serbia, University of Belgrade, 11000 Belg…. Die Arbeit nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science, Technological Development, and Innovation, Ministry of Science, Technological Development and Innovation of the Republic of Serbia.
Abstract (Originalsprache)
Background/Objectives: Multiple myeloma (MM) is an incurable, hematological malignancy caused by the abnormal proliferation of terminally differentiated plasma cells in the bone marrow. Current research indicates that N-azacytidine, as an epigenetic drug and nucleoside metabolic inhibitor, can be efficient in MM treatment. However, data on bone marrow mesenchymal stromal cells (BMSCs), as a critical cell population in the hematopoiesis and bone remodeling processes, are limited.
Methods
The effect of N-azacytidine on the myeloma cell line AMO-1, bone marrow mesenchymal stromal cells from MM patients (MM-MSCs) and patients undergoing hip arthroplasty (BMSCs) as a healthy control in hypoxia (3% O2) were examined. Cellular functions such as viability, proliferation, phenotype, and differentiation were determined by in vitro tests and flow-cytometry.
Results
N-azacytidine (100 nM to 1000 nM) significantly inhibited metabolic activity, cell cycle, CFSE dilution and CD138+/CD38+ expression levels by myeloma cells after 72 h. No viability changes were detected in MM-MSCs and BMSCs treated with N-azacytidine. As for both BMSCs and MM-MSCs differentiation potential, N-azacytidine did not affect alkaline phosphatase (ALP) activity and adipogenesis but inhibited matrix mineralization (500 nM and 1000 nM). However, when BMSCs were pretreated with N-azacytidine for 72 h, changes in ALP activity and mineralization level were not detected.
Conclusions
N-azacytidine, along with the suppressive effect on myeloma cells, did not change the differentiation potential of MSCs, but rather preserved their capacity. These findings are of particular importance considering MM progression and bone tissue destruction, suggesting that N-azacytidine may represent a promising therapeutic agent for myeloma disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Group for Hematology and Stem Cells, Institute for Medical Research, National Institute of the Republic of Serbia, University of Belgrade, 11000 Belgrade, Serbia.
- Center for Solid State Physics and New Materials, Institute of Physics, University of Belgrade, 11000 Belgrade, Serbia.
- Institute for Orthopaedics Banjica, 11000 Belgrade, Serbia.
- Clinic for Medical Oncology, Institute for Oncology and Radiology of Serbia, 11000 Belgrade, Serbia.
ORCID-Profile: Tamara Kukolj, Dragana Aleksandrović
Förderung
- Ministry of Science, Technological Development, and Innovation
- Ministry of Science, Technological Development and Innovation of the Republic of Serbia
Zitieren
APA
Kukolj, T., Spasić, A., Aleksandrović, D., Bogosavljević, N., Vujačić, M., Purić, M., Jauković, A., & Trivanović, D. (2026). N-Azacytidine Inhibits Myeloma Cell Growth While Preserving Multiple Myeloma Patient Derived-Bone Marrow Mesenchymal Stromal Cells Differentiation. Metabolites, 16(8), 540. https://doi.org/10.3390/metabo16080540
Vancouver
Kukolj T, Spasić A, Aleksandrović D, Bogosavljević N, Vujačić M, Purić M, et al. N-Azacytidine Inhibits Myeloma Cell Growth While Preserving Multiple Myeloma Patient Derived-Bone Marrow Mesenchymal Stromal Cells Differentiation. Metabolites. 2026;16(8):540. doi:10.3390/metabo16080540
BibTeX
@article{Kukolj2026,
author = {Kukolj, Tamara and Spasić, Anica and Aleksandrović, Dragana and Bogosavljević, Nikola and Vujačić, Marko and Purić, Mila and Jauković, Aleksandra and Trivanović, Drenka},
title = {N-Azacytidine Inhibits Myeloma Cell Growth While Preserving Multiple Myeloma Patient Derived-Bone Marrow Mesenchymal Stromal Cells Differentiation},
journal = {Metabolites},
year = {2026},
volume = {16},
number = {8},
pages = {540},
doi = {10.3390/metabo16080540}
}
EUVIMED